IL13RA2 and glioblastoma: Accordingly, a BsAb co-targeting IL-13Rα2 and CD16 is designed to redirect NK-mediated ADCC for selective elimination of IL-13Rα2-positive GBM cells and to enhance resilience against an immunosuppressive milieu.